| 2025 | 2024 | 2023 | ||||
|---|---|---|---|---|---|---|
| Gross margin | — | — | -5,3 M € | |||
| EBITDA | 240,0 k € | +102.8% | -8,6 M € | -33.7% | -6,4 M € | |
| Operating profit | -8,2 M € | +9.8% | -9,1 M € | -28.9% | -7,0 M € | |
| Profit/loss | -7,7 M € | +6.6% | -8,2 M € | -21.6% | -6,7 M € | |
| Equity | 10,7 M € | -41.7% | 18,3 M € | +26.1% | 14,5 M € | |
| Total assets | 12,5 M € | -41.8% | 21,5 M € | +7.4% | 20,0 M € | |
| Cash | 3,2 M € | -68.5% | 10,1 M € | +197.1% | 3,4 M € | |
| Debts | 978,2 k € | -46.4% | 1,8 M € | +13.3% | 1,6 M € | |
| Staff | 17,1 | 19,5 | 12,5 | |||
Public limited company · Leuven · incorporated on 04/07/2022 · 17,1 ETP
Public limited company loss-making in the latest fiscal year. Cash position declining (-68.5%).
Solid counterparty for a standard engagement.
AstriVax Therapeutics is a Public limited company incorporated in 2022. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Leuven. It employs on average 17,1 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette